CHECKLIST for Nurses and EMS Personnel
Administering Janssen COVID-19 VACCINE Under EUA
GMVEMSC JITSO for Paramedics and Adv. EMTs 3/1/2021

The Janssen COVID-19 Vaccine is a suspension for intramuscular injection for use in individuals **18** years of age and older, **administered as a single dose** (0.5 mL). For more information, see the full "EUA Fact Sheet for Providers." For the most recent Fact Sheet, please see www.janssencovid19vaccine.com.



Dose Preparation:

1. Store unpunctured multi-dose vials of the Janssen COVID-19 Vaccine at 2°C to 8°C (36°F to 46°F) and protect from light. Do not store frozen. Unpunctured vials of Janssen COVID-19 Vaccine may be stored between 9°C to 25°C (47°F to 77°F) for up to 12 hours.
   - **See EUA Fact Sheet for Providers for full process.**
2. The Janssen COVID-19 Vaccine is administered intramuscularly as a **single dose** (0.5 mL).
3. The Janssen COVID-19 Vaccine is a colorless to slightly yellow, clear to very opalescent suspension. Visually inspect the vaccine vials for particulate matter and discoloration prior to administration. If either of these conditions exists, do not administer the vaccine.
4. Before withdrawing each dose of vaccine, carefully mix the contents of the multi-dose vial by **swirling gently** in an upright position for 10 seconds. **Do not shake**.
5. Each dose is 0.5 mL. Each vial contains five doses. Do not pool excess vaccine from multiplevials.
6. The Janssen COVID-19 Vaccine does not contain a preservative. Record the date and time of first use on the Janssen COVID-19 Vaccine vial label. After the first dose has been withdrawn, hold the vial between 2° to 8°C (36° to 46°F) for up to 6 hours or at room temperature (maximally 25°C/77°F) for up to 2 hours. Discard if vaccine is not used withinthese times.

Vaccine Administration

Visually inspect each dose in the dosing syringe prior to administration. The Janssen COVID-19 Vaccine is a colorless to slightly yellow, clear to very opalescent suspension. During the visual inspection,

- verify the final dosing volume of 0.5 mL.
- confirm there are no particulates and that no discoloration is observed.
- do not administer if vaccine is discolored or contains particulate matter.

Administer the Janssen COVID-19 Vaccine intramuscularly.

IM Injections in Deltoid Muscle

- **Use proper landmarks and technique to identify the injection site**
- **Use proper needle length for age and size of patient**
- **Aspiration is not recommended when administering vaccines**



FIGURE 31.38 A method of establishing the deltoid muscle site for an intramuscular injection





Information and Reporting Requirements

1. The Janssen COVID-19 Vaccine is authorized for use in individuals 18 years of age and older.
2. Provide "Fact Sheet for Recipients and Caregivers" **prior** to giving the Vaccine.
3. The vaccination provider must include vaccination information in the state/local jurisdiction's Immunization Information System (IIS) or other designated system.
4. The vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS): vaccine administration errors whether or not associated with an adverse event, serious adverse events (irrespective of attribution to vaccination), cases of Multisystem Inflammatory Syndrome (MIS), and cases of COVID-19 that result in hospitalization or death.
   - Submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html.

Provide a vaccination card to the recipient or their caregiver with the name of the vaccine ("Janssen COVID-19 Vaccine") and date of administration to document vaccination.

Contraindication

Do not administer the Janssen COVID-19 Vaccine to individuals with a known history of a severeallergic reaction (e.g., anaphylaxis) to any component of the Janssen COVID-19 Vaccine *(see FullEUA Prescribing Information)*.

Warnings and Precautions

Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of COVID-19 Vaccine.
Monitor Janssen COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).

- **30 minutes:**
  - Persons with a history of an immediate allergic reaction of any severity to another (non-mRNA

COVID-19) vaccine or injectable therapy
    - Persons with a history of anaphylaxis due to any cause
- **15 minutes:** All other persons
- Media reports indicate there have been some syncopal episodes after the injection. These are likely vasovagal reactions to the injection; no indication of anything to do with the vaccine. Manage with positioning and supportive care.

Adverse Reactions

- Adverse reactions reported in a clinical trial following administration of the Janssen COVID-19 Vaccine include injection site pain, headache, fatigue, myalgia, nausea, fever, injection site erythema and injection site swelling. In clinical studies, severe allergic reactions, including anaphylaxis, have been reported following the administration of the Janssen COVID-19 Vaccine *(see Full EUA Prescribing Information)*.
- Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Janssen COVID-19 Vaccine.

Provide the v-safe information sheet to vaccine recipients/caregivers and encourage vaccine recipients to participate in v-safe. V-safe is a new voluntary smartphone-based tool that uses text messaging and web surveys to check in with people who have been vaccinated to identify potentialside effects after COVID-19 vaccination. V-safe asks questions that help CDC monitor the safetyof COVID-19 vaccines. V-safe also provides live telephone follow-up by CDC if participants report a significant health impact following COVID-19 vaccination. For more information, visit: www.cdc.gov/vsafe.